When comparing seizure freedom (12%–20%) and treatment failure due to adverse effects (8%–19%) after 3 months of follow-up in patients with non-BTRE receiving CLB as add-on,11 CLB does seem to perform quite similar in patients with glioma. This evidence concerns the gene CLYBL and central nervous system cancer.